{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T19:05:15Z","timestamp":1762542315653},"reference-count":38,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2014,12,1]],"date-time":"2014-12-01T00:00:00Z","timestamp":1417392000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pulmonary Pharmacology & Therapeutics"],"published-print":{"date-parts":[[2014,12]]},"DOI":"10.1016\/j.pupt.2014.08.005","type":"journal-article","created":{"date-parts":[[2014,8,27]],"date-time":"2014-08-27T19:32:25Z","timestamp":1409167945000},"page":"241-249","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"title":["Oral targeted therapies in the treatment of pulmonary arterial hypertension: A meta-analysis of clinical trials"],"prefix":"10.1016","volume":"29","author":[{"given":"Ya-Guo","family":"Zheng","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hong","family":"Ma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"En-Ci","family":"Hu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gang","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guo","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chang-Ming","family":"Xiong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.pupt.2014.08.005_bib1","doi-asserted-by":"crossref","first-page":"2493","DOI":"10.1093\/eurheartj\/ehp297","article-title":"Guidelines for the diagnosis and treatment of pulmonary hypertension","volume":"30","author":"Galie","year":"2009","journal-title":"Eur Heart J"},{"key":"10.1016\/j.pupt.2014.08.005_bib2","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1378\/chest.11-1460","article-title":"An evaluation of long-term survival from time of diagnosis in pulmonary arterial hypertension from the reveal registry","volume":"142","author":"Benza","year":"2012","journal-title":"Chest"},{"key":"10.1016\/j.pupt.2014.08.005_bib3","doi-asserted-by":"crossref","first-page":"343","DOI":"10.7326\/0003-4819-115-5-343","article-title":"Survival in patients with primary pulmonary hypertension. Results from a national prospective registry","volume":"115","author":"D'Alonzo","year":"1991","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.pupt.2014.08.005_bib4","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/j.pharmthera.2013.10.002","article-title":"Targeted therapies in pulmonary arterial hypertension","volume":"141","author":"Montani","year":"2014","journal-title":"Pharmacol Ther"},{"key":"10.1016\/j.pupt.2014.08.005_bib5","doi-asserted-by":"crossref","first-page":"811","DOI":"10.2165\/11538870-000000000-00000","article-title":"Targeted oral therapies in the treatment of pulmonary arterial hypertension","volume":"30","author":"Safdar","year":"2010","journal-title":"Clin Drug Investig"},{"key":"10.1016\/j.pupt.2014.08.005_bib6","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1038\/nrcardio.2011.104","article-title":"Treatment of pulmonary arterial hypertension with targeted therapies","volume":"8","author":"O'Callaghan","year":"2011","journal-title":"Nat Rev Cardiol"},{"key":"10.1016\/j.pupt.2014.08.005_bib7","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1093\/eurheartj\/ehp022","article-title":"A\u00a0meta-analysis of randomized controlled trials in pulmonary arterial hypertension","volume":"30","author":"Galie","year":"2009","journal-title":"Eur Heart J"},{"key":"10.1016\/j.pupt.2014.08.005_bib8","doi-asserted-by":"crossref","first-page":"1458","DOI":"10.1253\/circj.CJ-09-0971","article-title":"Meta-analysis of randomized controlled trials on treatment of pulmonary arterial hypertension","volume":"74","author":"He","year":"2010","journal-title":"Circulation J"},{"key":"10.1016\/j.pupt.2014.08.005_bib9","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1007\/s00228-013-1583-8","article-title":"Prostanoid therapy for pulmonary arterial hypertension: a meta-analysis of survival outcomes","volume":"70","author":"Zheng","year":"2014","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.pupt.2014.08.005_bib10","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1183\/09031936.00137511","article-title":"Selexipag: an oral, selective prostacyclin receptor agonist for the treatment of pulmonary arterial hypertension","volume":"40","author":"Simonneau","year":"2012","journal-title":"Eur Respir J"},{"key":"10.1016\/j.pupt.2014.08.005_bib11","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1056\/NEJMoa1209655","article-title":"Riociguat for the treatment of pulmonary arterial hypertension","volume":"369","author":"Ghofrani","year":"2013","journal-title":"N.\u00a0Engl J Med"},{"key":"10.1016\/j.pupt.2014.08.005_bib12","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1056\/NEJMoa1213917","article-title":"Macitentan and morbidity and mortality in pulmonary arterial hypertension","volume":"369","author":"Pulido","year":"2013","journal-title":"N.\u00a0Engl J Med"},{"key":"10.1016\/j.pupt.2014.08.005_bib13","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1378\/chest.12-2875","article-title":"Oral treprostinil for the treatment of pulmonary arterial hypertension in patients receiving background endothelin receptor antagonist and phosphodiesterase type 5 inhibitor therapy (The FREEDOM-C2 Study): a randomized controlled trial","volume":"144","author":"Tapson","year":"2013","journal-title":"Chest"},{"key":"10.1016\/j.pupt.2014.08.005_bib14","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1161\/CIRCULATIONAHA.112.124388","article-title":"Efficacy and safety of oral treprostinil monotherapy for the treatment of pulmonary arterial hypertension: a randomized, controlled trial","volume":"127","author":"Jing","year":"2013","journal-title":"Circulation"},{"key":"10.1016\/j.pupt.2014.08.005_bib15","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1378\/chest.11-2212","article-title":"Oral treprostinil for the treatment of pulmonary arterial hypertension in patients on background endothelin receptor antagonist and\/or phosphodiesterase type 5 inhibitor therapy (the FREEDOM-C study): a randomized controlled trial","volume":"142","author":"Tapson","year":"2012","journal-title":"Chest"},{"key":"10.1016\/j.pupt.2014.08.005_bib16","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1164\/rccm.201101-0093OC","article-title":"Vardenafil in pulmonary arterial hypertension: a randomized, double-blind, placebo-controlled study","volume":"183","author":"Jing","year":"2011","journal-title":"Am J Respir critical care Med"},{"key":"10.1016\/j.pupt.2014.08.005_bib17","doi-asserted-by":"crossref","first-page":"2894","DOI":"10.1161\/CIRCULATIONAHA.108.839274","article-title":"Tadalafil therapy for pulmonary arterial hypertension","volume":"119","author":"Galie","year":"2009","journal-title":"Circulation"},{"key":"10.1016\/j.pupt.2014.08.005_bib18","doi-asserted-by":"crossref","first-page":"521","DOI":"10.7326\/0003-4819-149-8-200810210-00004","article-title":"Addition of sildenafil to long-term intravenous epoprostenol therapy in patients with pulmonary arterial hypertension: a randomized trial","volume":"149","author":"Simonneau","year":"2008","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.pupt.2014.08.005_bib19","doi-asserted-by":"crossref","first-page":"2093","DOI":"10.1016\/S0140-6736(08)60919-8","article-title":"Treatment of patients with mildly symptomatic pulmonary arterial hypertension with bosentan (EARLY study): a double-blind, randomised controlled trial","volume":"371","author":"Galie","year":"2008","journal-title":"Lancet"},{"key":"10.1016\/j.pupt.2014.08.005_bib20","doi-asserted-by":"crossref","first-page":"3010","DOI":"10.1161\/CIRCULATIONAHA.107.742510","article-title":"Ambrisentan for the treatment of pulmonary arterial hypertension: results of the ambrisentan in pulmonary arterial hypertension, randomized, double-Blind, placebo-controlled, multicenter, efficacy (ARIES) study 1 and 2","volume":"117","author":"Galie","year":"2008","journal-title":"Circulation"},{"key":"10.1016\/j.pupt.2014.08.005_bib21","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1161\/CIRCULATIONAHA.106.630715","article-title":"Bosentan therapy in patients with Eisenmenger syndrome: a multicenter, double-blind, randomized, placebo-controlled study","volume":"114","author":"Galie","year":"2006","journal-title":"Circulation"},{"key":"10.1016\/j.pupt.2014.08.005_bib22","doi-asserted-by":"crossref","first-page":"2148","DOI":"10.1056\/NEJMoa050010","article-title":"Sildenafil citrate therapy for pulmonary arterial hypertension","volume":"353","author":"Galie","year":"2005","journal-title":"N.\u00a0Engl J Med"},{"key":"10.1016\/j.pupt.2014.08.005_bib23","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1183\/09031936.04.00028404","article-title":"Combination of bosentan with epoprostenol in pulmonary arterial hypertension: BREATHE-2","volume":"24","author":"Humbert","year":"2004","journal-title":"Eur Respir J"},{"key":"10.1016\/j.pupt.2014.08.005_bib24","doi-asserted-by":"crossref","first-page":"2119","DOI":"10.1016\/S0735-1097(03)00463-7","article-title":"Beraprost therapy for pulmonary arterial hypertension","volume":"41","author":"Barst","year":"2003","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.pupt.2014.08.005_bib25","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1056\/NEJMoa012212","article-title":"Bosentan therapy for pulmonary arterial hypertension","volume":"346","author":"Rubin","year":"2002","journal-title":"N.\u00a0Engl J Med"},{"key":"10.1016\/j.pupt.2014.08.005_bib26","doi-asserted-by":"crossref","first-page":"1496","DOI":"10.1016\/S0735-1097(02)01786-2","article-title":"Effects of beraprost sodium, an oral prostacyclin analogue, in patients with pulmonary arterial hypertension: a randomized, double-blind, placebo-controlled trial","volume":"39","author":"Galie","year":"2002","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.pupt.2014.08.005_bib27","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1016\/S0140-6736(01)06250-X","article-title":"Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebo-controlled study","volume":"358","author":"Channick","year":"2001","journal-title":"Lancet"},{"key":"10.1016\/j.pupt.2014.08.005_bib28","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0197-2456(95)00134-4","article-title":"Assessing the quality of reports of randomized clinical trials: is blinding necessary?","volume":"17","author":"Jadad","year":"1996","journal-title":"Control Clin trials"},{"key":"10.1016\/j.pupt.2014.08.005_bib29","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1136\/bmj.315.7109.629","article-title":"Bias in meta-analysis detected by a simple, graphical test","volume":"315","author":"Egger","year":"1997","journal-title":"Bmj"},{"key":"10.1016\/j.pupt.2014.08.005_bib30","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1111\/j.1365-2141.2010.08097.x","article-title":"Exercise capacity and haemodynamics in patients with sickle cell disease with pulmonary hypertension treated with bosentan: results of the ASSET studies","volume":"149","author":"Barst","year":"2010","journal-title":"Br J Haematol"},{"key":"10.1016\/j.pupt.2014.08.005_bib31","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1093\/eurheartj\/ehq011","article-title":"Combination therapy with bosentan and sildenafil in Eisenmenger syndrome: a randomized, placebo-controlled, double-blinded trial","volume":"31","author":"Iversen","year":"2010","journal-title":"Eur Heart J"},{"key":"10.1016\/j.pupt.2014.08.005_bib32","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/1465-9921-11-12","article-title":"Pharmacotherapy in pulmonary arterial hypertension: a systematic review and meta-analysis","volume":"11","author":"Ryerson","year":"2010","journal-title":"Respir Res"},{"key":"10.1016\/j.pupt.2014.08.005_bib33","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1378\/chest.13-1864","article-title":"Comparative effectiveness and safety of drug therapy for pulmonary arterial hypertension: a systematic review and meta-analysis","volume":"145","author":"Coeytaux","year":"2014","journal-title":"Chest"},{"key":"10.1016\/j.pupt.2014.08.005_bib34","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.pupt.2013.09.003","article-title":"Effectiveness and safety of macrolides in bronchiectasis patients: a meta-analysis and systematic review","volume":"28","author":"Shi","year":"2013","journal-title":"Pulm Pharmacol Ther"},{"key":"10.1016\/j.pupt.2014.08.005_bib35","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1016\/j.ajhg.2011.04.014","article-title":"Random-effects model aimed at discovering associations in meta-analysis of genome-wide association studies","volume":"88","author":"Han","year":"2011","journal-title":"Am J Hum Genet"},{"key":"10.1016\/j.pupt.2014.08.005_bib36","first-page":"CD004434","article-title":"Endothelin receptor antagonists for pulmonary arterial hypertension","volume":"2","author":"Liu","year":"2013","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.pupt.2014.08.005_bib37","first-page":"419","article-title":"A\u00a0randomized open label study comparing first-line treatment with bosentan or sildenafil in pulmonary arterial hypertension","volume":"33","author":"Mazzanti","year":"2012","journal-title":"Eur Heart J"},{"key":"10.1016\/j.pupt.2014.08.005_bib38","first-page":"82","article-title":"Macitentan and pulmonary arterial hypertension","volume":"370","author":"Pulido","year":"2014","journal-title":"N.\u00a0Engl J Med"}],"container-title":["Pulmonary Pharmacology & Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1094553914001047?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1094553914001047?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,30]],"date-time":"2018-09-30T07:53:47Z","timestamp":1538294027000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1094553914001047"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,12]]},"references-count":38,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2014,12]]}},"alternative-id":["S1094553914001047"],"URL":"https:\/\/doi.org\/10.1016\/j.pupt.2014.08.005","relation":{},"ISSN":["1094-5539"],"issn-type":[{"value":"1094-5539","type":"print"}],"subject":[],"published":{"date-parts":[[2014,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Oral targeted therapies in the treatment of pulmonary arterial hypertension: A meta-analysis of clinical trials","name":"articletitle","label":"Article Title"},{"value":"Pulmonary Pharmacology & Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pupt.2014.08.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}